With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, if you are willing to pay out of pocket for the medications.